应用新型出血风险评分个体化调整房颤患者抗凝治疗
基于RE-LY试验安全性人群(n=18 040),将VTE-BLEED评分校准为房颤适用的AF-BLEED评分,评估其预测大出血及与达比加群剂量交互作用。AF-BLEED识别19.6%高出血风险患者,其出血风险为低危者的2.9至3.4倍;高出血风险者随机接受110 mg每日两次的复合结局发生率低于150 mg组(RR 0.52,95%CI 0.35-0.78)。
要点
- AF-BLEED将19.6%房颤患者归为高出血风险,出血风险较低危者高2.9至3.4倍。
- 高出血风险患者用达比加群110 mg每日两次的复合结局风险低于150 mg组。
- AF-BLEED较说明书剂量下调标准多识别11%可能受益于剂量下调的患者。
核心结论
- AF-BLEED可识别房颤高出血风险患者,提示达比加群110 mg每日两次或可考虑用于此类患者。
研究设计与样本
- 在RE-LY试验安全性人群(n=18 040)中计算VTE-BLEED评分并校准为AF-BLEED,评估其对大出血的预测准确性及与达比加群剂量的交互作用。
主要发现
- AF-BLEED将3534例(19.6%)归为高出血风险,各治疗组中其出血风险为低危者的2.9至3.4倍。
- 高出血风险患者随机接受达比加群110 mg每日两次的复合结局发生率低于150 mg组,RR为0.52(95%CI 0.35至0.78)。
- 与说明书剂量下调标准相比,AF-BLEED多识别11%可能受益于剂量下调的患者。
关键数值与推荐
- AF-BLEED高出血风险:3534例(19.6%),出血风险为低危者的2.9至3.4倍。
- 高出血风险者达比加群110 mg每日两次对比150 mg每日两次的复合结局RR为0.52(95%CI 0.35至0.78)。
- AF-BLEED较说明书标准额外识别11%可能受益于剂量下调的患者。
临床怎么用
- 可考虑用AF-BLEED识别房颤高出血风险患者,并个体化选择达比加群剂量。
局限性
- 本研究为基于RE-LY试验的假设性分析,结果需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Current international guidelines advocate the application of bleeding risk scores only to identify modifiable risk factors, but not to withhold treatment in patients at high risk of bleeding. VTE-BLEED (ActiVe cancer, male with uncontrolled hyperTension, anaEmia, history of BLeeding, agE and rEnal Dysfunction) is a simple bleeding risk score that predicts major bleeding (MB) in patients with venous thromboembolism, but has never been evaluated in patients with atrial fibrillation (AF). We sought to evaluate VTE-BLEED in patients with AF included in the Randomised Evaluation of Long-term anticoagulant therapY (RE-LY) trial, to assess whether score classes (high vs low bleeding risk) interact with the tested dabigatran doses (150 vs 110 mg twice daily), and to investigate whether dose reductions based on this interaction might help to lower the incidence of the composite outcome MB, stroke/systemic embolism or death. METHODS: The score was calculated in the safety population of RE-LY (n=18 040) and recalibrated for AF (AF-adapted VTE-BLEED or AF-BLEED). HRs were calculated to evaluate the score's predictive accuracy for MB. The risk ratios (RRs) for the composite outcome comparing dabigatran 150 and 110 mg twice daily were calculated for the high-risk group. RESULTS: AF-BLEED classified 3534 patients (19.6%) at high bleeding risk, characterised by a 2.9-fold to 3.4-fold higher risk of bleeding than low bleeding risk patients, across the treatment arms. High bleeding risk patients randomised to 110 mg twice daily had a lower incidence of the composite outcome than those randomised to 150 mg twice daily, for an RR of 0.52 (95% CI 0.35 to 0.78). Compared with the label criteria for dose reduction, AF-BLEED identified an additional 11% of patients who might have benefited from dose reduction. CONCLUSIONS: AF-BLEED identified patients with AF at high risk of bleeding. Our findings raise the hypothesis that dabigatran 110 mg twice daily might be considered in patients classified as high risk according to the AF-BLEED score. This study provides a basis for future studies to explore safe dose reductions of direct oral anticoagulants in selected patient groups based on bleeding scores.
引用
- Chu G, Valerio L, van der Wall SJ, et al. Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. Heart. 2020. PMID: 32907824. doi:10.1136/heartjnl-2019-316305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。